The goal of this education is that clinicians will enhance their clinical capability and confidence in selecting, initiating, and managing complement-targeted therapies in patients with C3G and IC-MPGN, through real-world case applications addressing therapeutic decision-making, safety considerations, and ongoing monitoring.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
$54 – $4,128 per course
typical $950 · based on 60 courses listed here
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Foot & Ankle Surgery
- Gastroenterology
- General Internal Medicine
- General Pediatrics
- Head & Neck Surgery
- Interventional Radiology
- Medical Oncology
- Nephrology
- Neurology
- Neuromuscular Medicine
- Nuclear Medicine
- Obstetrics & Gynecology
- Pediatric Radiology
- Physical Medicine & Rehabilitation
- Pulmonary Disease
- Radiation Oncology
- Rheumatology
- Urological Oncology
- Vascular Neurology
- Vascular Surgery
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pediatrics
- Radiology
- Rehabilitation
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Case-based learning
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedJul 1, 2026
-
Last day to claim creditJul 1, 2028 2 years left
-
PeerVoice, Siyemi Europe Limited PeerVoice – 2025 Congress Highlights from Houston, Texas: Translating C3G and IC-MPGN Trials To Treatment in an Era of Complement Inhibition
-
PeerVoice, Siyemi Europe Limited PeerVoice – Emerging CAR-T Strategies in gMG and SPS: What Are We Learning About Their Therapeutic Potential?
-
PeerVoice, Siyemi Europe Limited PeerVoice – A Case-Based Masterclass Series: Guidelines to Practice in The Management of IgAN
